Zostavax

Zostavax is a shingles vaccine indicated for use in patients 50 and older. However, the presence of the live varicella zoster virus in the vaccine has actually caused some Zostavax patients to develop shingles.

What is Zostavax?

Zostavax is the only shingles vaccines approved for sale in the U.S. The vaccine was brought to market Merck & Co. in 2006, and was initially indicated for the prevention of shingles in patients aged 60 and over. In 2011, the U.S. Food & Drug Administration (FDA) approved Zostavax for the prevention of shingles in patients aged 50 and over.

Zostavax contains a weakened version of the live varicella zoster virus. Exposure to this weakened virus is intended to stimulate the body’s immune response without actually causing shingles.

Zostavax should not be administered to:

Pregnant women or those who may become pregnant

Immunosuppressed or immunodeficient patients

Individuals who are experiencing an acute illness or fever

People who have experienced a previous severe allergic reaction to gelatin or the antibiotic neomycin

What is Shingles?

Many people are exposed to the varicella zoster virus as children, when they develop chickenpox. Once a person has chickenpox, the virus remains dormant in their body for the rest of their life. Years later, the virus can reactivate, resulting in shingles.

Symptoms of shingles include:

Headache

Sensitivity to light

Flu-like symptoms without a fever

Itching, tingling, or pain where a band or strip of rash may appear several days or weeks later

Merck & Co. claims that Zostavax reduces the risk of shingles by about 51%. But according to an article published by the Health Sciences Institute in January 2016, UCLA researchers recently found that only one in 175 people who get the vaccine were actually spared a shingles flare-up.

Zostavax Side Effects and Complications

According to the National Vaccine Information Center, shingles-containing vaccines were cited in 1, 141 reports made to the Vaccine Adverse Events Reporting System between 1990 and September 1, 2015. More than a 1/3 of those adverse events occurred in seniors 65-75 years of age. The reports included 90 deaths, with 40% of the deaths occurring in seniors over 70 years of age.

In August 2014, the Zostavax label was updated to include shingles as a possible side effect. In February 2016, the labeling was modified to indicate that Zostavax had been linked to reports of “Eye Disorders: necrotizing retinitis (patients on immunosuppressive therapy)”.